@article {Cooper2022.01.30.22270042, author = {Scott E. Cooper and Th{\'e}oden I. Netoff}, title = {Multidimensional Bayesian Estimation for Deep Brain Stimulation Using the SafeOpt Algorithm}, elocation-id = {2022.01.30.22270042}, year = {2022}, doi = {10.1101/2022.01.30.22270042}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Some symptoms treated with Deep Brain Stimulation (DBS) such as gait in Parkinson{\textquoteright}s disease (PD), are often poorly responsive to DBS. This may be because DBS settings are usually optimized to other symptoms. To test this, we require an efficient, safe optimization algorithm. To develop such a tool, we extend the BayesOpt algorithm whose successful application to DBS settings we previously published [Louie et al 2021 J Neuroeng Rehabil], using, as a test bed, a simulated cost function constructed for biological plausibility, with measurement noise based on experimental data.We found that the SafeOpt algorithm [Sui et al 2015 Proc Machine Learning Res] converged to the optimum as well, and as fast as the BayesOpt algorithm, while avoiding high-cost points much more effectively. In three dimensions, SafeOpt converged in about 30 iterations, which is a feasible number for physical experiments in real patients. Convergence was slower when measurement nose was greater, but this could be overcome by running it for more iterations. The algorithm was relatively robust to misspecification of hyperparameters, and considerably more robust when hyperparameter fitting was incorporated into the algorithm. The algorithm did not perform as well when the quantization of stimulation settings was coarser, suggesting that it will work better with neurostimulators capable of independent current control. Finally, the algorithm was able to cope with a cost function having multiple local minima.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe first author received research support from National Institutes of Health (P50 NS123109) and The University of Minnesota Neuromodulation Innovations (MnDRIVE).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of University of Minnesota gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.}, URL = {https://www.medrxiv.org/content/early/2022/01/31/2022.01.30.22270042}, eprint = {https://www.medrxiv.org/content/early/2022/01/31/2022.01.30.22270042.full.pdf}, journal = {medRxiv} }